臨床外科71巻12号

2016年11月発行

特集 転移性肝腫瘍のいま—なぜ・どこが原発臓器ごとに違うのか 総論

転移性肝腫瘍治療の新たな展開

著者： 福岡聖大¹ 吉野孝之¹

所属機関： ¹国立がん研究センター東病院消化管内科

ページ範囲：P.1320 - P.1325

【ポイント】
◆転移性肝腫瘍は原発臓器ごとに治療方針を決定する．
◆肝切除などの局所療法と全身化学療法との集学的治療により長期生存する症例も少なからず存在する．
◆全身化学療法は免疫チェックポイント阻害薬を中心に新薬の開発が進んでいる．

参考文献

1）Iizuka T, Kakegawa T, Ide H, et al：Phase Ⅱ evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus：a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22：172-176, 1992

2）Mittal D, Gubin MM, Schreiber RD, et al：New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 27：16-25, 2014

3）Miki Y, Fujitani K, Hirao M, et al：Significance of surgical treatment of liver metastases from gastric cancer. Anticancer Res 32：665-670, 2012

4）Kinoshita T, Saiura A, Esaki M, et al：Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg 102：102-107, 2015

5）日本胃癌学会（編）：胃癌治療ガイドライン 医師用 2014年5月改訂，第4版．金原出版，2014

6）Swain SM, Baselga J, Kim SB, et al：Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372：724-734, 2015

7）Adam R, Pascal G, Azoulay D, et al：Liver resection for colorectal metastases：the third hepatectomy. Ann Surg 238：871-883；discussion 883-874, 2003

8）de Jong MC, Pulitano C, Ribero D, et al：Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis：an international multi-institutional analysis of 1669 patients. Ann Surg 250：440-448, 2009

9）Beppu T, Sakamoto Y, Hasegawa K, et al：A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection：multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19：72-84, 2012

10）大腸癌研究会（編）：大腸癌治療ガイドライン 医師用 2014年版．金原出版，2014

11）Nordlinger B, Sorbye H, Glimelius B, et al：Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC 40983）：long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14：1208-1215, 2013

12）Lam VW, Spiro C, Laurence JM, et al：A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19：1292-1301, 2012

13）Adam R, Wicherts DA, de Haas RJ, et al：Patients with initially unresectable colorectal liver metastases：is there a possibility of cure? J Clin Oncol 27：1829-1835, 2009

14）Ruers T, Punt C, Van Coevorden F, et al：Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases：a randomized EORTC Intergroup phase Ⅱ study（EORTC 40004）. Ann Oncol 23：2619-2626, 2012

15）van Hazel GA, Heinemann V, Sharma NK, et al：SIRFLOX：Randomized phase Ⅲ trial comparing first-line mFOLFOX6（plus or minus bevacizumab）versus mFOLFOX6（plus or minus bevacizumab）plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34：1723-1731, 2016

16）Loupakis F, Cremolini C, Masi G, et al：Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371：1609-1618, 2014

17）Le DT, Uram JN, Wang H, et al：PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372：2509-2520, 2015

18）Valle J, Wasan H, Palmer DH, et al：Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362：1273-1281, 2010

19）Okusaka T, Nakachi K, Fukutomi A, et al：Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer：a comparative multicentre study in Japan. Br J Cancer 103：469-474, 2010

20）Geynisman DM, Catenacci DV：Toward personalized treatment of advanced biliary tract cancers. Discov Med 14：41-57, 2012

21）Ross JS, Wang K, Catenacci DV, et al：Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol 33（suppl3）：abstr 231, 2015

22）Conroy T, Desseigne F, Ychou M, et al：FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364：1817-1825, 2011

23）Von Hoff DD, Ervin T, Arena FP, et al：Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369：1691-1703, 2013

24）Okusaka T, Ikeda M, Fukutomi A, et al：Phase Ⅱ study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105：1321-1326, 2014

25）Hingorani SR, Harris WP, Hendifar AE, et al：High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage Ⅳ previously untreated pancreatic cancer patients with high-HA tumors：Interim results of a randomized phase Ⅱ study. J Clin Oncol 33（suppl）：abstr 4006, 2015

26）Touzios JG KJ, Pitt SC, Rilling WS, et al：Neuroendocrine hepatic metastases：does aggressive management improve survival? Ann Surg 241：776-785, 2005

27）Rinke A, Muller HH, Schade-Brittinger C, et al：Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors：a report from the PROMID Study Group. J Clin Oncol 27：4656-4663, 2009

28）Raymond E, Dahan L, Raoul JL, et al：Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364：501-513, 2011

29）Yao JC, Shah MH, Ito T, et al：Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364：514-523, 2011